SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001213900-20-030520
Filing Date
2020-10-07
Accepted
2020-10-07 17:01:24
Documents
6
Effectiveness Date
2020-10-07

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE ADDITIONAL MATERIALS ea127848-defa14a_actinium.htm DEFA14A 45206
2 GRAPHIC proxy_001.jpg GRAPHIC 2533
3 GRAPHIC proxy_002.jpg GRAPHIC 5279
4 GRAPHIC proxy_003.jpg GRAPHIC 5719
5 GRAPHIC proxy_004.jpg GRAPHIC 4638
6 GRAPHIC proxy_005.jpg GRAPHIC 9318
  Complete submission text file 0001213900-20-030520.txt   84861
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36374 | Film No.: 201229582
SIC: 2834 Pharmaceutical Preparations